Local vs Systemic Methotrexate in Management of Uterine Ectopic Pregnancy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age20-40
SponsorTanta University
About this trial
This study aims to compare local and systemic methotrexate in the management of uterine ectopic pregnancy regarding the duration of beta human chorionic gonadotropin (hCG) clearance and need for further management options.
Eligibility criteria
Qualifiers
Age from 20 to 40 years.
Women with uterine ectopic pregnancy (interstitial pregnancy, cervical pregnancy, or cesarean scar pregnancy).
Gestational age is less than 9 weeks, the embryo size is smaller than 10 mm, and the serum beta-human chorionic gonadotropin (β-hCG) levels are less than 10,000 mIU/mL.
Disqualifiers
Patients with basal beta hCG levels less than 1500 mIU/Ml.
Any contraindications to MTX as a hepatic disorder, renal disorder and thrombocytopenia
Diabetes mellitus.
Severe vaginal bleeding or hemodynamic changes or hemoperitoneum.
Trial design
Treatments tested in this trial
- Systemic Methotrexate
- Local Methotrexate
Treatment groups
34 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov